Cedar Brook Financial Partners, LLC Seagen Inc. Transaction History

Cedar Brook Financial Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 04, 2023	BUY	$127.59 - $203.08 $148,514 - $236,385	1,164 New	1,164 $235,000
Q3 2022 Jan 03, 2023	SELL	$135.27 - $180.11 $811 - $1,080	-6 Reduced 0.39%	1,533 $209,000
Q2 2022 Aug 12, 2022	BUY	$108.81 - $179.33 $3,046 - $5,021	28 Added 1.85%	1,539 $272,000
Q1 2022 Apr 06, 2022	BUY	$119.61 - $157.85 $6,339 - $8,366	53 Added 3.64%	1,511 $218,000
Q4 2021 Jan 27, 2022	BUY	$142.57 - $190.86 $3,279 - $4,389	23 Added 1.6%	1,458 $225,000

Q3 2021 Nov 01, 2021	SELL	$142.45 - $169.82 $45,299 - $54,002	-318 Reduced 18.14%	1,435 $244,000
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $11,076 - $13,210	82 Added 4.91%	1,753 $277,000
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $275,096 - $354,135	1,671 New	1,671 $293,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Cedar Brook Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Cedar Brook Financial Partners, LLC with notifications on news.